Deciphera Pharmaceuticals is testing an investigational drug called ripretinib (DCC-2618) as a potential new treatment option for patients living with GIST.
Ripretinib is an oral investigational drug designed to treat GISTs that are growing because of changes in specific genes. By targeting the inhibition of signals from the genes that cause cancer to grow and spread ripretinib may provide benefit to patients living with GIST.
The INTRIGUE study is a Phase 3 clinical trial testing the investigational drug ripretinib (DCC-2618) for patients living with GIST that are no longer on imatinib due to progression or intolerance. The study is being conducted to learn more about the safety of DCC-2618 and how well it works against cancer, as compared to sunitinib (Sutent), in patients who have previously received imatinib (Gleevec).
Approximately 358 GIST patients will participate in the trial worldwide. In addition to meeting other eligibility criteria, patients may be eligible to join the study if they:
• Are at least 18 years old
• Have been diagnosed with GIST and received prior treatment with imatinib only
• Are willing and able to comply with study procedures
Please note that DCC-2618 has not been approved by the United States Food and Drug Administration (FDA) or any other regulatory agencies for sale or use by the public.
The information contained wherein is provided solely to inform patients about the existence of this trial, and does not in any way constitute an endorsement by the LRG nor is it intended to serve as medical advice. Any questions about how this trial may fit into your overall treatment plan should be discussed with your healthcare team. Sutent and Gleevec are approved for the treatment of GIST by the FDA and other regulatory bodies around the world.